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SUMMARY: An apparent Mr variant of plasma transth-yretin (TTR), previously 
detected using 2-D PAGE, is the first reported occurrence of this type of human TTR 
variant. We characterized the variant TTR to determine the nature of this difference. 
Comparative tr-yptic peptide maps of variant and normal TTR and sequencing of 
peptides which differed indicated the variant contained a single amino acid substitution 
of valine for tyrosine at position 116. Because such a change requires two nucleotide 
substitutions, we postulate the variant arose through mutation in codon 116 of a 
heretofore unrecognized polymorphic or rare variant allele of TTR. o 1987 Academic Press, 
Inc. 
In the course of our studies of genetic variat,ion of plasma proteins in 56 
Caucasoid families, an apparent molecular weight variant of transthyretin (TTR, 
formerly thyroxine-binding prealbumin) was discovered (1). The variant appeared in 
two generations in healthy adult individuals in a family of French Canadian descent. 
Other reports of human genetic variation in TTR have appeared. Asakawa et al. (2) 
detected one electrophoretic variant which was more cathodal than normal TTR in a 
study of 109 Japanese families. Altland et a1.(3) have detected 3 different 
electrophoretic variants of TTR in the German population. Two had PI’S more basic 
and one more acidic than normal TTR. One of the basic variants was observed in 7 
families and the other two variants were observed each in a single family in a study of 
4,000 non-related families. Lalloz et al. (4) have detected a genetic variant TTR which 
has increased affinity for T4 but which is indistinguishable from normal TTR by both 
isoelectric focusing and SDS PAGE. To our knowledge, the only reported instances of 
genetic variation in TTR for which the amino acid substitution has been identified have 
been in individuals affected with familial amyloidotic pal-yneuropathy (FAP). In type I 
FAP of Japanese, Portuguese, Swedish and Greek origins the genetic lesion has been 
identified as a valine to methionine substitution at position 30 of TTR (5-8). In the case 
of type I FAP of Jewish origin, the amino acid substitution is isoleucine for 
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phenylalanine at position 33 (9). Type II FAP of Indiana/Swiss origin has a serine for 
isoleucine at position 64 (10) and the Appalachian type has alanine for threonine at 
position 60 (11). 
The current investigation describes the characterization of the apparent M 
r 
variant of TTR which we have detected. In addition we describe the implementation of 
a purification procedure at the nanomole level which is useful when sample size is 
limiting. 
MATERIALS AND METHODS 
Materials: Serum or plasma was prepared from proband (AP) peripheral blood following 
informed consent. Human plasma transth.yretin (CalBiochem) was used as a control. 
Purification of TTR: TTR was isolated from serum of the proband (AP): heterozygous for 
TTR, by an&exchange HPLC essentially as previously described (12). AP serum (1.3 
ml containing - 10 nmole TTR) was injected on an AX300 column (IOmp, 4 x 100 mm . 
S~ynchrome. Linden. IN) equilibrated with 4mM Na phosphate, pH 7.8. Protein was 
eluted with a Na phosphate gradient as described in the legend to Figure 2. TTR was 
identified by double immunodiffusion using rabbit antibody to human TTR 
(CalBiochem) and verified by 2D-PAGE. Fractions containing TTR were pooled, diluted 
with an equal volume of deionized water and chromatographed a second time on an 
AX300 column except that the buffers were adjusted to pH 7.0. TTR was further 
purified by affinity chromatography on Affi-Gel Blue to remove the bulk of 
contaminating albumin and retinol-binding protein (7). TTR containing fractions were 
pooled. dialyzed against water and lyophilized. Protein was reconstituted with 
phosphate buffered saline (PBS) and separated on a gel permeation column (I-125, 7 x 
250mm, Waters) equilibrated with PBS at a flow rate of 0.7 mbmin. TTR was further 
purified by reverse phase I-IPLC on a C4 column (10 mp, 4 x lOOmm, Vydac). The 
reverse phase column was equilibrated with 0.1% trifluoroacetic acid (TFA) in water. 
Protein was eluted with a 0.05% TFA in MeCN gradient as described in Figure 3. 
2-D polyacrylamide gel electrophoresis: Two-dimensional polyacrylamide gel 
electrophoresis of plasma and HPLC column effluent fractions was as previously 
described (13). Plasma 2-D gels were stained with Coomassie Brilliant Blue ‘R-250 for 
screening for TTR variants. 2-D gels of HPLC column effluent fractions were silver 
stained by the method of Merril el al. (14). Immunoblots on nitrocellulose were a 
modification of the method of Burnett (15) as previously described (16). First antibody 
was rabbit anti-TTR or rabbit anti-retinol-binding protein (CalBiochem). Second 
antibody was horseradish peroxidase conjugated goat anti-rabbit IgG (Sigma). 4-chloro- 
I-naphthol was used as substrate. 
Tryptic peptide mapping: Normal TTR and AP-TTR were treated with 707~ formic acid 
for 12 hr (9) at room temuerature and lsonhilized. Each was then digested with trvnsin 
(Miles) treated with L-l-Lsylamido-2-phenylethyl chloromethyl ketone (TPCK) in 0.2 M 
ammonium bicarbonate, pH 8.2, for 2 hr at 37” (enzyme/substrate, E/S, ratio=1/50, wi 
w). A second aliquot of TPCK-tr-ypsin was added and the digestion continued for an 
additional 18 hr (final E/S ratio= l/25, w/w). Digests were acidified with glacial acetic 
acid, lyophilized, and peptides separated by reverse phase HPLC on a column of Cl8 
PBondapak (Waters) as described in the legend to Figure 4. Peptides not completely 
resolved were further chromatographed on the same column using isopropanolMeCN (li 
2, v/v) in place of MeCN. 
Amino acid analysis and sequence determination: Amino acid analyses were performed 
asdesczdbyrr7) for PTC-amino acids separated by reverse phase HPLC. 
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Sequence analyses of selected peptides were by the manual sequence film method with 
polybrene of Tarr (17). Occasionally, a gas phase sequencer (Applied Biosystems) was 
used for extended sequences. PTH-derivatives were identified by reverse phase HPLC, on 
an Ult.rasphere ODS column developed with a step gradient in 88mM ammonium 
acetate, pH 4.9, of 25 to 51% MeCN (17). Occasionally, identification of a PTH-amino 
acid was confirmed by chromatography on a Nova-Pak Cl8 column developed with a 
gradient of 100 mM K phosphate vs 84% MeCN as previously described (17). 
RESULTS AND DISCUSSION 
A section of a 2-D gel of normal plasma and AP-plasma. from an individual 
heterozygous for the TTR variant. is shown in Figure 1A. Normal TTR appears as two 
spots of equal Mr: the more anodic form being much less intense. The variant TTR is 
seen as having a higher apparent molecular weight than normal TTR. The variant is 
present in slightly reduced amounts relative to normal TTR. bot.h on silver stained gels 
(Figure 1A) and Coomassie Blue stained gels (not shown). The corresponding region of 
an immunoblot. probed with anti-TTR. is shown in Figure 1B. Both normal and variant 
spots react with anti-TTR with approximately equal intensity after peroxidase staining. 
No other pal-ypeptides cross-react with anti-TTR. 
Initial fractionation of serum by anion exchange HPLC (Figure 2A) resulted in the 
elution of TTR in two peaks, the first representing the TTR tetramer and the second the 
TTR-retinol binding protein (RBP) complex. Both fractions contained normal and 
variant TTR as determined by 2-D PAGE of individual fractions. TTR containing 
fractions were pooled, diIuted with water and chromatographed a second time on an 
anion exchange HPLC column (Figure 2B and 2C) using a modified buffer pH and 
gradient to remove additional albumin. TTR was again eluted in two peaks (TTR 
tetramer and TTR-RBP complex, Figure 2C), each containing normal and variant TTR. 
Affinity chromatography on AffiGel Blue was then performed to remove RBP and any 
remaining albumin (not shown). After lyophilization and reconstitution of the sample. 
the TTR was applied to a gel permeation column. The TTR containing peak comprised 
normal AP 
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Figure 1. A section of a 2-D gel of normal and AP plasma. The normal (N) and variant 
(V) TTR on (A) silver stained gels and (B) immunoblots with anti-TTR. 
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Figure 2. Anion exchange HPLC of AP serum. (A) AP serum (1.3ml) was injected on 
an AX300 column equilibrated with buffer A: 4mM sodium phosphate, pH7.3. Buffer 
B: 0.4M sodium phosphate, pH 7.6. Gradient: O-308 B in 30 min then 30-605 B in 10 
min. Flow rate: 0.7mUmin. Bars indicate fractions immunoreactive with anti-TTR (a) 
or with anti-RBP (b). (B) and (C) Rechromatography of fractions immunoreactive to 
anti-TTR only or to anti-TTR and anti-RBP. respectively. Buffers A and B were 
adjusted to pH 7.0. Gradient: lo-30% B in 30 min. 
50% of the 280nm absorbing material and contained both normal and variant TTR (not 
shown). AP-TTR was further purified by reverse phase HPLC on a C4 column (Vydac), 
using TFA as ion pairing agent and development with a MeCN gradient (Figure 3). 
Normal and variant TTR’s were co-purified through this step and appeared 
homogeneous as judged by 2-D electrophoresis. 
Purified AP-TTR, containing both normal and variant TTR, was digested with 
trypsin. Tryptic peptides were separated by reverse phase HPLC on a Cl8 PBondapak 
column (Figure 4). Two new peptides, Tll-12-13” and T12-13*, were found in the 
tr-yptic peptide map of AP-TTR (bottom) compared to that of normal TTR (top). In 
addition, the corresponding normal peptide was present in reduced amount in the 
mixture and in approximately the same amount as the variant peptide. Yields of 
individual tryptic peptides were low due to the extensive B pleat structure of TTR which 
confers substantial resistance to the protein to tryptic digestion (7). Fifty picomole of 
the variant and normal peptides Tll-12-13 were obtained for microsequence analysis. 
Reliable amino acid sequence information was obtained for the first 13 cycles of Edman 
degradation. By comparison with the published sequence for TTR (18); both peptides 
were identified as beginning at residue 104 in the C-terminal region of TTR (127 total 
residues). An amino acid difference was found at cycle 13 (residue 116) where the 
normal peptide had a tyrosine and the variant peptide had a valine. Such an amino 
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Figure 3. Reverse phase HPLC of AP-TTR from the gel permeation step. Column: 
Vydac C4 equilibrated with solvent A: 0.1 F TFA in water. Solvent B: 0.05% TFA in 
MeCN. Gradient: O-605 B in 45 min. Flow rate: lml/min. The bar indicates TTR 
containing fractions. 
acid substitution would require two nucleotide changes. Since no residues could be 
reliably confirmed beyond cycle 13. the possibility of a frame shift was not excluded. 
Thus we repeated the purification and digestion of TTR from a second sampling of .4P 
NN 
I I I I 1 
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Figure 4. Reverse phase HPLC of TTR tryptic peptides. Column: Cl6 pBondapak 
equilibrated with solvent A: 0.1% TFA in water. Solvent B: 0.05% TFA in MeCN. 
Gradient: O-605 B in 60 min. Flow rate: lmlmin. (Top) normal, NN, and (bottom) AP- 
TTR, NV, tryptic peptides. 
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serum and isolated and sequenced the variant peptides. The second digestion was 
performed using more stringent digestion conditions to improve the yield of the variant 
peptide. TTR was denatured in 70% formic acid (9). lyophilized and digested twice with 
trypsin (final ES ratio=1:25). The variant peptides Tll-12-13” and T12-13” were 
isolated for sequencing. Amino acid analysis indicated that the peptides consisted of 
residues 104 to 127 and 105 to 127, respectively, the C-terminus. Microsequencing of 
Tl l-12-13” -yielded positive identification of the ammo acids in 16 of 18 cycles. The 
sequence, arg-t.~-thr-ile-ala-ala-leu-leu-ser-pro-t-~-ser-VAL-ser- ? - ? -ala-val- 
(val,thr,asx,pro,lys,glu). was obtained. Residues in parentheses are from the amino acid 
composition and their order is inferred from the published sequence (18). The difference 
of a valine instead of t-yrosine at cycle 13 was confirmed. A valine for tyrosine at 
residue 116 was also confirmed in peptide T12-13”. In addition, serine, alanine and 
valine were confirmed at residues 117, 120 and 121, respectively, in agreement with the 
published sequence for normal TTR. The expected threonine residues at residues 118 
and 119 could not be confirmed in either peptide Tl l-12-13” or T12-13%. The sequence 
and amino acid composition of the variant peptides thus exclude a frame shift as the 
mechanism of obtaining a valine for t-yrosine at residue 116. 
The substitution of valine for tyrosine requires two nucleotide substitutions. 
Therefore we propose that the variant TTR arose from a mutation in a rare variant or 
heretofore undetected polymorphic allele of human TTR. There are two possibilities 
(phenylalanine or glutamic acid at residue 116) for the proposed “intermediate” allele. 
Glutamic acid at residue 116 would result in a polypeptide more anodal than normal 
TTR and which could focus in the position of the minor isoform of normal TTR (Figure 
1). We have not detected such an anodal spot nor an increase in the intensity of the 
minor spot. Altland et al. (3) have detected a rare electrophoretic variant with a pI 
more acidic than normal TTR in one of 4,000 families studied. However, the amino 
acid substitution has not been determined. Alternatively, a neutral substitution of 
phenylalanine for t-yrosine could have gone undetected and could be a likely candidate 
for an undetected variant or polymorphic “intermediate”. 
The mechanism for the difference in mobility in the SDS dimension between the 
normal and variant TTR monomers is unclear. Slight. differences in conformation or in 
the extent of SDS binding to the denatured polypeptide as a result of the substitution of 
valine for t-yrosine could account for the mobility difference. Single amino acid 
substitutions in actin (19) and in hypoxanthineguanine phosphoribosyl transferase (20) 
have also been shown to result in apparent molecular weight differences in the 
respective allelic poleypeptides in SDS PAGE. 
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